[Ip-health] Evidence-Based Incentives - WHA - 22May @1800
ahollis at ucalgary.ca
Thu May 17 09:10:29 PDT 2012
Your participation is invited at the following WHA side event. This interactive meeting will offer an opportunity to connect current evidence on pay-for-performance mechanisms with ideas on how rewards could be set in prize-type mechanisms (possibly in the context of the proposed R&D convention).
“Can Evidence-Based Incentives Improve Drug Development and Delivery?” Side Event at the 65th World Health Assembly, Palais des Nations, Room XII, 22 May 2012, 18h00 to 19h30
An important thrust of pharmaceutical policy internationally in recent years is the increasing reliance on systematic evidence as a guide to prioritizing spending. This may not only lead to more efficient allocation of limited resources, but can also affect the behavior of companies, which respond to long-term predictable spending priorities when making decisions about investing in research. Governments and international institutions around the world have been experimenting with pay-for-performance mechanisms that attempt to align private incentives to invest in drug discovery and delivery with measured health outcomes.
This meeting will examine how using evidence about systematic effectiveness of new medicines can increase the efficiency of spending and improve private sector incentives. Attendees will hear brief presentations from distinguished leaders on their experience and proposals related to evidence-based incentives for drug development and delivery and then participate in an extended interactive discussion about how incentives can be harnessed at both national and global levels.
Speakers will include:
* Dr Christoph Benn, Director of External Relations & Partnerships, Global Fund to Fight AIDS, Tuberculosis & Malaria, Switzerland, on “The Global Fund contribution to Access to Medicines and its market dynamics strategy”
* Dr Kalipso Chalkidou, Director, NICE International, United Kingdom, on “Using Evidence of Comparative Clinical and Cost-Effectiveness as a Lever in Pharmaceutical Policy”
* Prof Thomas Pogge, President, Incentives for Global Health, and Leitner Professor of Philosophy & International Affairs, Yale University, USA, on “Basing Innovation Rewards for Pharmaceuticals and Health Technologies on Actual Performance”
* Prof John-Arne Røttingen, Board Chair, Alliance for Health Policy & Systems Research; Chair, WHO’s Consultative Expert Working Group on Research & Development; and Professor, Institute of Health & Society, University of Oslo, Norway
Discussion will be led by Abdul Ghaffar, Executive Director, Alliance for Health Policy & Systems Research.
We very much hope you will be able to join us for what will no doubt be an enlightening and productive meeting. Please let us know if you have any questions in advance of the meeting.
* Steven J. Hoffman (hoffmans at mcmaster.ca), Advisor, Incentives for Global Health, and Assistant Professor of Clinical Epidemiology & Biostatistics, McMaster University, Canada
* Abdul Ghaffar (ghaffara at who.int), Executive Director, Alliance for Health Policy & Systems Research, World Health Organization
The listing in the WHA Journal is available at http://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_JourP-en.pdf
I look forward to meeting many of you there.
Professor of Economics
University of Calgary, 2500 University Dr NW Calgary AB T2N 1N4 Canada
tel: +1 403 220 5861 fax: +1 403 220 5861
email: ahollis at ucalgary.ca
Incentives for Global Health
Keep up with the Health Impact Fund by "liking" it at
More information about the Ip-health